Depression is one of the most common mental health conditions in the world, affecting hundreds of millions of people.
It can cause persistent sadness, loss of interest in daily activities, low energy, sleep problems, difficulty concentrating, and feelings of hopelessness.
While many people benefit from antidepressant medications and psychological therapies, a significant number continue to struggle despite trying multiple treatments.
Doctors refer to this as treatment-resistant depression. For these patients, finding effective treatment options can be extremely difficult.
Some individuals spend years trying different medications without achieving meaningful improvement. This challenge has motivated researchers to search for entirely new ways to treat depression.
A study led by researchers at the University of Bristol offers a promising new direction. The research, published in JAMA Psychiatry on May 20, investigated whether an existing immune-system drug could help people whose depression had not responded to standard antidepressants.
The drug, called tocilizumab, is already used to treat inflammatory diseases such as rheumatoid arthritis. Instead of targeting brain chemicals like serotonin, it works by blocking part of the body’s immune response.
Scientists became interested in this approach because growing evidence suggests that inflammation may play an important role in depression for some people.
For decades, most depression research focused on chemical messengers in the brain. Many antidepressants aim to increase levels of serotonin, dopamine, or norepinephrine.
While these treatments help many patients, they do not work for everyone. Researchers have increasingly realized that depression is likely not a single disease but a collection of conditions with different biological causes.
One area receiving considerable attention is the immune system. Studies have found that about one-third of people with depression show elevated levels of inflammatory markers in their blood.
These markers suggest that their immune systems may be unusually active. Scientists believe this chronic low-grade inflammation could affect brain function and contribute to depressive symptoms.
Previous research from the Bristol team pointed to a specific inflammatory pathway involving a protein called interleukin-6, or IL-6. This protein helps regulate immune activity throughout the body. Higher levels of IL-6 have repeatedly been linked to depression, leading researchers to wonder whether blocking its effects might improve mental health.
To test this idea, the team conducted a randomized controlled trial involving 30 adults with moderate-to-severe treatment-resistant depression. All participants also showed evidence of low-grade inflammation based on blood tests. Fourteen participants received tocilizumab, while sixteen received a placebo made from saltwater. The study lasted four weeks.
Although the trial was relatively small, the results were encouraging. Participants receiving tocilizumab generally showed greater improvements in depression symptoms than those receiving the placebo. Improvements were also seen in anxiety, fatigue, and overall quality of life.
One particularly interesting finding involved remission rates. More than half of the participants receiving tocilizumab achieved remission, meaning their depression symptoms improved substantially. In comparison, fewer participants in the placebo group reached remission. The researchers calculated a Number Needed to Treat of five, suggesting that five patients would need treatment for one additional patient to benefit compared with placebo.
The findings support the growing idea that some forms of depression may have strong biological links to inflammation. If future research confirms these results, doctors may eventually be able to identify patients with inflammatory depression through blood tests and offer more personalized treatments.
Researchers emphasize that much more work is needed before tocilizumab could become a standard depression treatment. Larger studies involving hundreds or thousands of participants will be necessary to confirm both safety and effectiveness.
Still, the study represents an important shift in depression research.
Rather than treating all patients the same way, scientists are increasingly exploring treatments tailored to a person’s biology. This personalized approach could eventually improve outcomes for many people who do not respond to current therapies.
